Lumia E, Fabiani E, Bielli P, Sarchi M, Senatore M, Fiducioso C, Hajrullaj H, Iannini C, Rasicci M, Silvestrini G, Lelli N, Onorato A, Cristiano A, Pieraccioli M, Mallegni F, Moretti F, Guarnera L, Falconi G, Hutter S, Nadarajah N, Haferlach T, Malcovati L, Sette C, Voso M. CO36 | TGF-β pathway deregulation in SF3B1-mutated low risk myelodysplastic syndrome patients: E. Lumia1, E. Fabiani2|3, P. Bielli2, M. Sarchi4, M. Senatore2, C. Fiducioso4, H. Hajrullaj2, C. Iannini4, M. Rasicci2, G. Silvestrini2, N. Lelli1, A. Onorato2, A. Cristiano1|5, M. Pieraccioli6|7, F. Mallegni2, F. Moretti2, L. Guarnera1, G. Falconi2, S. Hutter8, N. Nadarajah8, T. Haferlach8, L. Malcovati4|9, C. Sette2, M.T. Voso2 | 1Department of Biomedicine and Prevention, PhD program in immunology, molecular medicine and applied biotechology, University of Tor Vergata; 2Department of Biomedicine and Prevention, University of Tor Vergata; 3UniCamillus-Saint Camillus International University of Health Sciences; 4Department of Molecular Medicine, University of Pavia; 5Operative Research Unit of Laboratory, Fondazione Policlinico Universitario Campus Bio-Medico; 6Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Hearth; 7GSTEP-Organoids Core Facility, Fondazione Policlinico Agostino Gemelli IRCCS; 8MLL Munich Leukemia Laboratory; 9Department of Hematology, Fondazione IRCCS Policlinico S. Matteo. haematol [Internet]. 2026Mar.3 [cited 2026Aug.21];111(s1). Available from: https://haematologica.org/article/view/haematol.2026.s1.44